isoxazoles has been researched along with Carcinoma, Renal Cell in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furukawa, S; Handa, H; Hashimoto, A; Hashimoto, S; Mikami, S; Oikawa, T; Okada, Y; Onodera, Y; Oya, M; Sabe, H; Sugino, H; Yoshikawa, A | 1 |
| Chen, Y; Hu, X; Huang, Q; Li, T; Wang, Y; Zhou, H | 1 |
| Carbone, PP; Davis, TE; Earle, JD; Elson, PJ; Glover, DJ; Hahn, RG; Kvols, LK; Trump, DL; Vogl, SE | 1 |
3 other study(ies) available for isoxazoles and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.
Topics: ADP-Ribosylation Factor 6; ADP-Ribosylation Factors; Adult; Aged; Aged, 80 and over; Amides; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Female; GTP-Binding Protein alpha Subunits, G12-G13; Guanine Nucleotide Exchange Factors; HEK293 Cells; Humans; Immunohistochemistry; Indoles; Isoxazoles; Kidney Neoplasms; Lysophospholipids; Male; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Nerve Tissue Proteins; Propionates; Pyridines; Pyrroles; Receptors, Lysophosphatidic Acid; Signal Transduction; Sirolimus; Sunitinib; Triazoles | 2016 |
Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; beta Catenin; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Humans; Isoxazoles; Leflunomide; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Signal Transduction; Wnt3A Protein | 2016 |
Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma.
Topics: Adult; Aged; Alanine; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Evaluation; Female; Humans; Isoxazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxazoles; Thiadiazoles; Vinblastine | 1988 |